ies. This research is being funded in part by a grant awarded to Dr. Ujendra Kumar from the Natural Sciences and Engineering Research Council of Canada (NSERC).

InMed has filed an international patent application demonstrating neuroprotection and enhanced neuronal function using rare cannabinoids and analogs for the potential treatment of neurodegenerative diseases such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease and others. The patent specifies such compounds that may inhibit or slow the progression of neurodegenerative diseases by providing neuroprotection in a population of affected neurons.





About InMed:

InMed Pharmaceuticals is a global leader in the research, development, manufacturing and commercialization of rare cannabinoids, including clinical and preclinical

programs targeting the treatment of diseases with high unmet medical needs. We also have significant know-how in developing proprietary manufacturing approaches to produce cannabinoids for various market sectors. For more information, visit www.inmedpharma.com and www.baymedica.com.











Investor Contact:



Colin Clancy

Vice President, Investor Relations

and Corporate Communications

T: +1.604

© Edgar Online, source Glimpses